Halozyme Therapeutics, Inc. · NASDAQ:HALO

Halozyme Therapeutics — Q2 2026 Earnings Presentation

15 slides from Halozyme Therapeutics's earnings presentation, Aug 6, 2026

  1. Slide 1: Second Quarter 2026 Financial & Operating Results

    Halozyme Therapeutics, Inc. Second Quarter 2026 Financial & Operating Results Nasdaq: HALO August 6, 2026 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking Non-GAAP Financial Measures: statements including, without limitation, statements concerning the Company’s expected future financial performance and growth rates (i

  3. Slide 3: Strong Execution Continues Across the Business in 2Q 2026

    Strong Execution Continues Across the Business in 2Q 2026 Commercial ENHANZE® portfolio drove record royalty revenue growth of 50% • Increasing contributions from recently launched Opdivo® SC, Ocrevus® SC and Rybrevant® SC to royalty revenues • Continued strong growth of DARZALEX® SC and VYVGART® Hy

  4. Slide 4: Record 2Q 2026 Financial Results

    Record 2Q 2026 Financial Results $481.0M $307.7M Total Revenue Royalty Revenue +48% +50% $2.28 $328.8M Non-GAAP Adjusted EBITDA1 Diluted EPS1 +46% +48% $332.8M Shares repurchased in 2Q 2026 1 Reconciliation between GAAP reported and Non-GAAP financial information for actual results are provided at t

  5. Slide 5: Raising 2026 Financial Guidance

    Raising 2026 Financial Guidance 2025 Prior 2026 Updated 2026 Change from Prior Guidance Actuals GUIDANCE1 GUIDANCE at Midpoint Total $1,396.6 $1.710B – 1.810B $1.835B – 1.910B $112.5M Revenue Royalty $867.8 $1.130B – 1.170B $1.220B – 1.245B $82.5M Revenue Adjusted EBITDA $657.6 $1.125B – 1.205B $1.2

  6. Slide 6: Current Launched ENHANZE Portfolio Driving Growth 2026-2028

    Current Launched ENHANZE® Portfolio Driving Growth 2026-2028 Emerging Growth Drivers | Increasing royalty contributions DARZALEXZUNOVO OCREVUS FASPRO® RYBREVANT FASPRO OPDIVO Qvantig® ✓ Ocrevus Zunovo® drives global growth ✓ Rapid uptake following SC launch ✓ ~44,000 patients on Ocrevus® SC ✓ Strong

  7. Slide 7: Drivers of Revenue 2029+

    Drivers of Revenue 2029+ 1 2 3 10 Current Launched 13 Projected ENHANZE® 2 Projected Hypercon ENHANZE® Products Launches in 2029+ Launches in 2030/2031 • Generated 25% of projected • 9 ENHANZE® targets currently in • Invest in manufacturing capacity potential royalties to end 2025 development • 2 Ph

  8. Slide 8: Delivered on Goal for New Collaboration and Licensing Agreements in 2026

    Delivered on Goal for New Collaboration and Licensing Agreements in 2026 ENHANZE® Hypercon ✓ Multiple promising oncology targets ✓ First ENHANZE® collaboration in antibody drug conjugates ✓ Enabling use for up to 3 ✓ Upfront payment, milestones and Vertex targets royalties ✓ Upfront payment, milesto

  9. Slide 9: Robust ENHANZE Royalty Revenue Growth

    Robust ENHANZE® Royalty Revenue Growth Total DARZALEX® IV+SC Revenue VYVGART® & VYVGART® Hytrulo Revenue PHESGO® Revenue Based on Analyst Estimates 1 Based on Analyst Estimates2 Based on Analyst Estimates1 ($B) ($B) ($B) $8.6 $3.9 $20.6 $3.8 $18.9 $7.2 $3.6 $16.9 $5.9 $3.0 $14.4 $4.1 2Q 2Q $4.2B $1.

  10. Slide 10: 2Q 2026 Financial Highlights

    2Q 2026 Financial Highlights $ in Millions, except EPS (unaudited) 2Q 2026 2Q 2025 % Change Royalties $307.7 $205.6 50% Product sales, net $129.6 $81.5 59% Collaboration revenues $43.7 $38.6 13% Total Revenues $481.0 $325.7 48% Cost of sales $79.2 $46.4 71% Amortization of intangibles $29.5 $17.8 66

  11. Slide 11: Substantial Cash Flow Generation Provides Significant Flexibility for Disciplined Capital Allocation

    Substantial Cash Flow Generation Provides Significant Flexibility for Disciplined Capital Allocation Maximize Organic Return Capital to Deleveraging M&A Investments Shareholders Plan to retire the 2027 and 2028 remaining notes at Repurchased $332.8 million maturity Maximize the value of during quart

  12. Slide 12: Royalty Momentum Drives Strong 2026 Guidance Update

    Royalty Momentum Drives Strong 2026 Guidance Update 2025 Prior 2026 Updated 2026 YOY Actuals GUIDANCE1 GUIDANCE CHANGE (%) • Growth primarily driven by increases in royalty revenue and product sales Total • Product sales are expected to track relatively $1,396.6 $1.710B – 1.810B $1.835B – 1.910B 31%

  13. Slide 13: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations 13

  14. Slide 14: GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA

    GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA $ in thousands (Unaudited) (1) Adjustment relates to litigation costs incurred by Halozyme in connection with Halozyme’s patent infringement litigation against Merck Sharp & Dohme LLC (“Merck”). These charges are excluded because the Compan

  15. Slide 15: GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS

    GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS $ in thousands, except per share amounts (Unaudited) (1) Adjustment relates to litigation costs incurred by Halozyme in connection with Halozyme’s patent infringement litigation against Merck. These charges are excluded because the Company

Halozyme Therapeutics — Q2 2026 Earnings Presentation on 6ix